Extended-release tacrolimus in stable child liver transplant recipients
Part of Digestive system clinical trials.
This study tests an extended-release version of the anti-rejection drug tacrolimus in children who have already had a stable liver transplant. The goal is to see if the longer-acting capsule works as well as the immediate-release form, potentially simplifying daily medication routines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 18 years old or younger and has had a liver transplant.
- Your child can swallow capsules whole.
- Your child has been taking the immediate-release form of tacrolimus for at least 3 months.
- Blood counts, liver and kidney function, and blood clotting are normal, and doctors consider your child stable.
- Your child is scheduled for a planned liver biopsy as part of this study.
- Your child is not allergic to tacrolimus and has not taken the extended-release form before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
This trial tests if switching from a standard twice-daily tacrolimus to a once-daily prolonged-release version is safe and effective for liver transplant recipients who have stable liver function. It aims to simplify your medication schedule.
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
This trial tests whether children who had a liver transplant before age 6 can safely stop taking their anti-rejection medicine. It's for children who are doing well — with normal liver function and no signs of rejection or scarring — at least 4 years after transplant.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.